Business
Satellos Bioscience Inc. Invited to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 26, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Inc. Invited to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferenceToronto, Ontario--(Newsfile Corp. - April 26, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (\"Satellos\" or the \"Corporation\"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Satellos Bioscience was invited to present at the 2022 Bloom Burton & Co. Healthcare Investor Conference. The conference brings together U.S., Canadian, and international investors interested in the latest developments in the Canadian healthcare sector.Event: 2022 Bloom Burton & Co. Healthcare Investor ConferenceWhen: Monday May 2 - Tuesday May 3, 2022 8:30AM-4:30 PM ETWhere: Metro Toronto Convention Centre, North Building 255 Front St W, Toronto, OntarioFrank Gleeson, Satellos Bioscience's Chief Executive Officer, will deliver a presentation on Tuesday, May 3 at 2:30pm ET and will also host one-on-one meetings throughout the conference.To watch Satellos Bioscience's presentation live, please visit the Investors-News & Events section of the corporate website @ www.satellos.com or join using the following link: https://wsw.com/webcast/bloomburton7/mscl.v/3095998About DuchenneDuchenne is a fatal genetic disease that slowly and progressively robs people of their muscle strength and function. Diagnosed in childhood, affecting approximately one in 5,000 live male births, Duchenne is caused by a change in the dystrophin gene. It was discovered by Dr. Michael Rudnicki that muscle stem cells in people living with Duchenne are severely compromised in their ability to create the muscle progenitor cells upon which repair and regeneration depend. As a result, the muscles of Duchenne patients are unable to keep up with the continuous damage that accumulates throughout life, becoming progressively more damaged. No treatment exists today to correct this situation.About Bloom Burton & Co.Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our cl...